Dashboard
Manage Tickers

JNJJOHNSON & JOHNSON

NYSE jnj.com


$ 160.21 $ 1.32 (0.83 %)    

Thursday, 08-Aug-2024 15:59:54 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 449.23 $ 13.30 (3.06 %)
DIA $ 395.05 $ 6.75 (1.74 %)
SPY $ 531.28 $ 11.99 (2.31 %)
TLT $ 95.30 $ -0.59 (-0.62 %)
GLD $ 224.00 $ 3.46 (1.57 %)
$ 160.22
$ 160.18 x 200
$ 160.31 x 400
-- - --
$ 141.57 - $ 170.63
5,050,546
na
388.05B
$ 0.47
$ 10.21
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-25-2024 06-30-2024 10-Q
2 05-01-2024 03-31-2024 10-Q
3 02-16-2024 12-31-2023 10-K
4 10-27-2023 10-01-2023 10-Q
5 10-27-2023 10-01-2023 10-Q
6 07-31-2023 07-02-2023 10-Q
7 04-28-2023 04-02-2023 10-Q
8 02-16-2023 01-01-2023 10-K
9 10-27-2022 10-02-2022 10-Q
10 07-29-2022 07-03-2022 10-Q
11 04-29-2022 04-03-2022 10-Q
12 02-17-2022 01-02-2022 10-K
13 10-29-2021 10-03-2021 10-Q
14 07-29-2021 07-04-2021 10-Q
15 04-30-2021 04-04-2021 10-Q
16 02-22-2021 01-03-2021 10-K
17 10-23-2020 09-27-2020 10-Q
18 07-24-2020 06-28-2020 10-Q
19 04-29-2020 03-29-2020 10-Q
20 02-18-2020 12-29-2019 10-K
21 10-28-2019 09-29-2019 10-Q
22 07-29-2019 06-30-2019 10-Q
23 05-01-2019 03-31-2019 10-Q
24 02-20-2019 12-30-2018 10-K
25 10-31-2018 09-30-2018 10-Q
26 08-02-2018 07-01-2018 10-Q
27 05-01-2018 04-01-2018 10-Q
28 02-21-2018 12-31-2017 10-K
29 11-02-2017 10-01-2017 10-Q
30 08-03-2017 07-02-2017 10-Q
31 05-08-2017 04-02-2017 10-Q
32 02-27-2017 01-01-2017 10-K
33 11-04-2016 10-02-2016 10-Q
34 08-04-2016 07-03-2016 10-Q
35 05-10-2016 04-03-2016 10-Q
36 02-24-2016 01-03-2016 10-K
37 10-30-2015 09-27-2015 10-Q
38 07-31-2015 06-28-2015 10-Q
39 05-01-2015 03-29-2015 10-Q
40 02-24-2015 12-28-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

johnson--johnson-announces-groundbreaking-nipocalimab-study-of-pregnant-individuals-at-high-risk-for-early-onset-severe-hemolytic-disease-of-the-fetus-and-newborn-published-in-the-new-england-journal-of-medicine
Johnson & Johnson Announces Groundbreaking...
08/07/2024 21:41:32

Nipocalimab delayed or prevented severe fetal anemia and 54 percent of study participants in the Phase 2 UNITY study achieved a...

cantor-fitzgerald-reiterates-overweight-on-johnson--johnson-maintains-215-price-target
Cantor Fitzgerald Reiterates Overweight on...
08/05/2024 18:07:14

Cantor Fitzgerald analyst Louise Chen reiterates Johnson & Johnson (NYSE:JNJ) with a Overweight and maintains $215 price...

looking-at-johnson--johnsons-recent-unusual-options-activity
Looking At Johnson & Johnson's Recent Unus...
08/02/2024 19:32:53

comparative-study-johnson-amp-johnson-and-industry-competitors-in-pharmaceuticals-industry
Comparative Study: Johnson & Johnson A...
08/01/2024 15:00:50

fda-says-do-not-use-megadyne-mega-soft-pediatric-patient-return-electrodes-in-any-age-group-only-use-megadyne-mega-2000-mega-soft-patient-return-electrodes-on-patients-12-years--older
FDA Says Do Not Use Megadyne Mega Soft Ped...
07/31/2024 19:35:50

- Reuters Citing FDA 

reported-earlier-johnson--johnsons-darzalex-faspro-quadruplet-therapy-approved-by-fda-for-initial-treatment-of-multiple-myeloma
Reported Earlier, Johnson & Johnson's DARZ...
07/31/2024 07:05:05

Findings from first-ever quadruplet therapy study with subcutaneous DARZALEX FASPRO® showed 60 percent reduction in risk of d...

bristol-myers-johnson--johnson-abbvie-astrazeneca-expect-minimal-impact-from-upcoming-medicare-price-negotiations
Bristol Myers, Johnson & Johnson, AbbVie, ...
07/30/2024 18:12:15

Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact fro...

cantor-fitzgerald-reiterates-overweight-on-johnson--johnson-maintains-215-price-target
Cantor Fitzgerald Reiterates Overweight on...
07/30/2024 14:07:27

Cantor Fitzgerald analyst Louise Chen reiterates Johnson & Johnson (NYSE:JNJ) with a Overweight and maintains $215 price...

a-closer-look-at-14-analyst-recommendations-for-johnson--johnson
A Closer Look at 14 Analyst Recommendation...
07/30/2024 14:01:36

rbc-capital-reiterates-outperform-on-johnson--johnson-maintains-175-price-target
RBC Capital Reiterates Outperform on Johns...
07/30/2024 12:36:54

RBC Capital analyst Shagun Singh reiterates Johnson & Johnson (NYSE:JNJ) with a Outperform and maintains $175 price target.

johnson--johnson-unusual-options-activity-for-july-29
Johnson & Johnson Unusual Options Activity...
07/29/2024 20:45:54

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
07/26/2024 17:35:23

courts-congress-likely-to-stand-in-way-of-jjs-third-texas-two-step-plan-us-court-of-appeals-for-3rd-circuit-latest-to-reject-unprecedented-bankruptcy-strategy-lawyers-on-behalf-of-ovarian-cancer-victims-are-calling-on-johnson--johnson-to-end-its-war-of-attrition-against-cancer-victims
Courts, Congress Likely To Stand In Way Of...
07/26/2024 13:42:03

U.S. Court of Appeals for 3rd Circuit latest to reject unprecedented bankruptcy strategyLawyers on behalf of tens of thousands ...

looking-into-johnson--johnsons-recent-short-interest
Looking Into Johnson & Johnson's Recent Sh...
07/25/2024 13:15:25

newly-listed-psoriasis-focused-alumis-attracts-analysts-attention-with-promising-lead-program-and-modest-valuation
Newly-Listed Psoriasis-Focused Alumis Attr...
07/24/2024 19:18:10

Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis an...

check-out-what-whales-are-doing-with-jnj
Check Out What Whales Are Doing With JNJ
07/24/2024 16:01:23

pharma-giant-johnson--johnson-asks-fda-to-approve-esketamine-nasal-spray-for-treatment-resistant-depression
Pharma Giant Johnson & Johnson Asks FDA To...
07/23/2024 17:20:03

daiwa-capital-downgrades-johnson--johnson-to-neutral-lowers-price-target-to-150
Daiwa Capital Downgrades Johnson & Johnson...
07/23/2024 09:35:17

Daiwa Capital analyst Narumi Nakagiri downgrades Johnson & Johnson (NYSE:JNJ) from Outperform to Neutral and lowers the ...

bidens-exit-from-presidential-race-yet-another-curveball-for-equity-investors-analysts
Biden's Exit From Presidential Race 'Yet A...
07/22/2024 18:54:41

President Biden's decision to drop out may harm healthcare and create market volatility. Kamala Harris could defend his rec...

after-disappointing-data-johnson--johnson-halts-developing-epilepsy-drug-candidate
After Disappointing Data, Johnson & Johnso...
07/22/2024 13:15:49

Addex Therapeutics announces Janssen Pharmaceuticals, a Johnson & Johnson unit, has halted ADX71149 development for epileps...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION